• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/18

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

18 Cards in this Set

  • Front
  • Back

Trimethoprim- sulfamethoxazole


MOA

Synergistic combination of folate antagonist blocks purine production and nucleic acid synthetis

Trimethoprim- sulfamethoxazole


Effects

Bactericidal activity against susceptible bacteria

Trimethoprim- sulfamethoxazole


Clinical use

Urinary tract infections


Respiratory tract, ear and sinus


P jiroveci pneumonia


Toxoplasmosis


Nocardiosis

Trimethoprim- sulfamethoxazole


PK


Toxicity


Interactions

Oral, IV


Renal clearance•half life 8h• dosed every 8-12 h• formulated in 5:1 ratio of sulfamethoxazole to trimethoprim


Toxicity


Rash, fever, bone marrow suppression, hyperkalemia

Sulfisoxazole

Oral


Only for lower urinary infections

Sulfadiazine+ pyrimethamine

Oral, first line therapy for toxoplasmosis

Trimethoprim

Oral


Only for lower urinary tract infections


Safe for patients with sulfonamide allergy

Pyrimethamine

Oral


First line therapy for toxoplasmosis with sulfadiazine


Coadministration with leucovorin to limit bone marrow toxicity

Pyrimethamine- sulfadoxine

Oral


Second line malaria treatment

Ciprofloxacin


MOA & effects

Inhibits DnA replication by binding to DNA gyrase and topoisomerase IV



Bactericidal against susceptible bacteria

Ciprofloxacin


Clinical use

Urinary tract infection


Gastroenteritis travellers diarrhea


Osteomyelitis


Anthrax


Activity vs gonococci rapidly declining


Limited use in tuberculosis

Ciprofloxacin


PK, toxicity, interactions

Oral, IV


Mixed clearance, mostly renal


half life 4h


Dosed every 12h


Divalent and trivalent cations impair oral absorption


Toxicity


GI upsets


Neurotoxicity (dizziness, headache)


Tendinitis due to effects on cartilage (avoid in young children and pregnancy)

Ofloxacin

Oral


Has improved pharmacokinetics and pharmacodynamics


Limited to urinary tract infections and nongonococcal urethritis and cervicitis


Eradicates chlamydiae trachomatis in 7d treatment

Levofloxacin

Oral, IV


L-isomer of ofloxacin


Once daily dosing


Renal clearance


Respiratory fluoroquinolone with improved activity versus pneumococcus


Active against community acquired pneumonia including


Chlamydiae, mycoplasma, legionella

Moxifloxacin

Oral, IV


Respiratory fluoroquinolone


Once daily dosing


Improved activity vs anaerobes and m tuberculosis


Hepatic clearance results in lower urinary levels- use in urinary tract infections is Not recommended

Gemifloxacin

Oral


Respiratory fluoroquinolone

Subclasses of fluoroquinolone

1. Generation


Norfloxacin



2. generation


Ofloxacin


Ciprofloxacin




3. Generation


Levofloxacin



4. Generation


Moxifloxacin



Gemifloxacin

Subclass of folate antagonists

Trimethoprim- sulfamethoxazole


Sulfisoxazole


Sulfadiazine + Pyrimethamine


Trimethoprim


Pyrimethamine + sulfadoxine